Golimumab
- Generic Name
- Golimumab
- Brand Names
- Simponi
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 476181-74-5
- Unique Ingredient Identifier
- 91X1KLU43E
- Background
Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate treatment in patients with moderate to se...
- Indication
Used in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) in patients 2 years old and above with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS) or in combination with methotrexate, and (iv) as a single agent in patients w...
- Associated Conditions
- Active Polyarticular Juvenile Idiopathic Arthritis (pJIA), Severe Ulcerative Colitis, Active Ankylosing spondylitis, Active Psoriatic arthritis, Moderate Ulcerative colitis, Moderate, active Rheumatoid arthritis, Severe, active Rheumatoid arthritis
- Associated Therapies
- -
Study of Subcutaneous Golimumab in Chinese Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy
- Conditions
- Interventions
- First Posted Date
- 2010-11-25
- Last Posted Date
- 2013-09-06
- Lead Sponsor
- Centocor, Inc.
- Target Recruit Count
- 264
- Registration Number
- NCT01248780
Effect of SAR153191 (REGN88) With Methotrexate in Patients With Active Rheumatoid Arthritis Who Failed TNF-α Blockers
- Conditions
- Interventions
- First Posted Date
- 2010-10-08
- Last Posted Date
- 2017-09-01
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 16
- Registration Number
- NCT01217814
- Locations
- 🇲🇽
Investigational Site Number 484008, Durango, Mexico
🇨🇴Investigational Site Number 170004, Barranquilla, Colombia
🇨🇴Investigational Site Number 170005, Barranquilla, Colombia
An Effectiveness and Safety Study of Intravenous Golimumab in Patients With Active Rheumatoid Arthritis Despite Treatment With Methotrexate Therapy
- Conditions
- Interventions
- First Posted Date
- 2009-09-09
- Last Posted Date
- 2013-12-25
- Lead Sponsor
- Centocor, Inc.
- Target Recruit Count
- 592
- Registration Number
- NCT00973479
A Study to Evaluate the Safety and Effectiveness of Ustekinumab or Golimumab Administered Subcutaneously (SC) in Patients With Sarcoidosis
- First Posted Date
- 2009-08-10
- Last Posted Date
- 2014-07-17
- Lead Sponsor
- Centocor, Inc.
- Target Recruit Count
- 173
- Registration Number
- NCT00955279
A Study of Safety and Effectiveness of Golimumab in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy
- Conditions
- Interventions
- First Posted Date
- 2006-08-08
- Last Posted Date
- 2014-07-29
- Lead Sponsor
- Centocor, Inc.
- Target Recruit Count
- 643
- Registration Number
- NCT00361335
An Efficacy and Safety Study of CNTO 148 Subcutaneous Injection Compared With Placebo in Patients With Active Rheumatoid Arthritis
- Conditions
- Interventions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2012-10-18
- Lead Sponsor
- Centocor, Inc.
- Target Recruit Count
- 172
- Registration Number
- NCT00207714
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.